1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.heares.2015.07.002" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.heares.2015.07.002</a>
Pages
59–66
Volume
328
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Canertinib induces ototoxicity in three preclinical models.
Publisher
An entity responsible for making the resource available
Hearing research
Date
A point or period of time associated with an event in the lifecycle of the resource
2015
2015-10
Subject
The topic of the resource
Animals; Antineoplastic Agents/*adverse effects/pharmacology; Antitumor; Auditory; Canertinib; Carcinoma; Drug Screening Assays; Ear; Electrophysiology; ERBB; ErbB Receptors/*antagonists & inhibitors; Female; Hair Cells; Hearing Loss/*chemically induced; Hearing/*drug effects; Inbred C57BL; Inbred CBA; Lung Neoplasms/drug therapy; Male; Mice; Morpholines/*adverse effects/pharmacology; Neuregulin-1/metabolism; Non-small cell lung cancer; Non-Small-Cell Lung/drug therapy; NRG1; Ototoxicity; Outer hair cell; Outer/*drug effects; Signal Transduction/drug effects; Zebrafish
Creator
An entity primarily responsible for making the resource
Tang Jian; Qian Yi; Li Hui; Kopecky Benjamin J; Ding Dalian; Ou Henry C; DeCook Rhonda; Chen Xiaojie; Sun Zhenyu; Kobel Megan; Bao Jianxin
Description
An account of the resource
Neuregulin-1 (NRG1) ligand and its epidermal growth factor receptor (EGFR)/ERBB family regulate normal cellular proliferation and differentiation in many tissues including the cochlea. Aberrant NRG1 and ERBB signaling cause significant hearing impairment in mice. Dysregulation of the same signaling pathway in humans is involved in certain types of cancers such as breast cancer or non-small cell lung cancer (NSCLC). A new irreversible pan-ERBB inhibitor, canertinib, has been tested in clinical trials for the treatment of refractory NSCLC. Its possible ototoxicity was unknown. In this study, a significant dose-dependent canertinib ototoxicity was observed in a zebrafish model. Canertinib ototoxicity was further confirmed in two mouse models with different genetic backgrounds. The data strongly suggested an evolutionally preserved ERBB molecular mechanism underlying canertinib ototoxicity. Thus, these results imply that clinical monitoring of hearing loss should be considered for clinical testing of canertinib or other pan-ERBB inhibitors.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.heares.2015.07.002" target="_blank" rel="noreferrer noopener">10.1016/j.heares.2015.07.002</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2015
Animals
Antineoplastic Agents/*adverse effects/pharmacology
Antitumor
Auditory
Bao Jianxin
Canertinib
Carcinoma
Chen Xiaojie
DeCook Rhonda
Department of Anatomy & Neurobiology
Ding Dalian
Drug Screening Assays
Ear
Electrophysiology
ERBB
ErbB Receptors/*antagonists & inhibitors
Female
Hair Cells
Hearing Loss/*chemically induced
Hearing research
Hearing/*drug effects
Inbred C57BL
Inbred CBA
Kobel Megan
Kopecky Benjamin J
Li Hui
Lung Neoplasms/drug therapy
Male
Mice
Morpholines/*adverse effects/pharmacology
NEOMED College of Medicine
Neuregulin-1/metabolism
Non-small cell lung cancer
Non-Small-Cell Lung/drug therapy
NRG1
Ototoxicity
Ou Henry C
Outer hair cell
Outer/*drug effects
Qian Yi
Signal Transduction/drug effects
Sun Zhenyu
Tang Jian
Zebrafish